The “Targeted Protein Degradation Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade.
Key Inclusions
§ A detailed assessment of the current market landscape oftargeted protein degradation-based therapeutics, providing information on drug/ therapy developer(s) (such as year of establishment, company size andlocation of headquarters), clinical study sponsor(s) and collaborator(s), typeof protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobictags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostaticmodulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phaseof development (clinical, preclinical, and discovery stage) of productcandidates, target indication(s), key therapeutic area(s), type of targetprotein(s), target enzyme(s) (if available), target signaling pathway (ifavailable), mechanism of action (if available), type of therapy(monotherapy and combination therapy), route of administration (oral,intravenous and others), and information on special drug designations (ifany). In addition, the chapter highlights the various technology platformsthat are being actively used for the development of targeted protein degraders.
§ Elaborate profiles of key players that are engaged in thedevelopment of targeted protein degraders (shortlisted on the basis of phaseof development of pipeline products), featuring a brief overview of thecompany, its financial information (if available), detailed descriptionsof their respective lead drug candidates, and an informed future outlook.Additionally, each drug profile features information on the type of drug, routeof administration, target indications, current status of development and abrief summary of its developmental history.
§ Brief tabulated profiles of industry players (shortlistedon the basis of the number of pipeline products), featuring details on theinnovator company (such as year of establishment, location of headquarters,number of employees, and key members of the executive team), recentdevelopments, along with descriptions of their respective drug candidates.
§ A detailed clinical trial analysis of completed, ongoingand planned studies of various targeted protein degraders, highlightingprevalent trends across various relevant parameters, such as current trialstatus, trial registration year, enrolled patient population and regionaldistribution of trials, type of protein degrader, phase of development, studydesign, leading industry and non-industry players (in terms of number oftrials conducted), study focus, target therapeutic area, key indications,and clinical endpoints.
§ An assessment of the relative experience of key opinionleaders (KOLs) within this domain, (shortlisted based on their involvementin various clinical studies), featuring detailed 2X2 matrices (based onthe strength and activeness of KOLs), a schematic world map representation(highlighting the geographical locations of eminent scientists / researchers)and an analysis evaluating the (relative) level of expertise of different KOLs,based on parameters such as number of publications, number of citations,participation in clinical trials, number of affiliations and strength ofprofessional network (based on information available on ResearchGate).
§ A detailed publication analysis of more than 210peer-reviewed, scientific articles that have been published since 2017,highlighting the research focus within the industry. It also highlights the keytrends observed across the publications, including information on novel proteindegraders, potential target proteins, target disease indications, and analysisbased on various relevant parameters, such as year of publication, and mostpopular journals (in terms of number of articles published in the given timeperiod) within this domain.
§ An analysis of the partnerships that have been establishedin the domain, over the period 2014-Q3 2019, covering research agreements,product / technology licensing agreements, mergers / acquisitions, assetpurchase agreements, R&D and commercialization agreements, IP licensingagreements, clinical trial agreements, product development agreements, andother relevant deals.
§ An analysis of the investments made at various stages ofdevelopment, such as seed financing, venture capital financing, debt financing,grants / awards, capital raised from IPOs and subsequent offerings, bycompanies that are engaged in this field.
The report also features thelikely distribution of the current and forecasted opportunity across importantmarket segments, mentioned below:
§ Type of payment oflicensing agreements
§ Upfront payments
§ Milestone payments
§ Type of proteindegrader
§ Degronimids
§ PROTACs
§ SARDs / SERDs
§ Specific BET and DUBinhibitors
§ Other proteindegraders
§ Therapeutic area
§ Neurodegenerativedisorders
§ Oncological disorders
§ Other therapeuticareas
§ Route ofadministration
§ Oral
§ Intravenous
§ Other routes
§ Key geographicalregion
§ North America
§ Europe
§ Asia-Pacific
Torequest a sample pages, please visit this link
Key Questions Answered
§ What are theprevalent R&D trends related to targeted protein degradation?
§ Which clinicalconditions can be treated using targeted protein degradation-based therapeutics?
§ Whatare the most popular proteins being targeted by bifunctional degradermolecules?
§ What are the keychallenges faced by stakeholders engaged in this domain?
§ What are the keytechnology platforms that leverage the concept of targeted protein degradation?
§ Whoare the leading industry and non-industry players in this market?
§ Whatare the contributions of big pharma players in this field?
§ Whatare the key geographies where research on targeted protein degradation is beingconducted?
§ Whoare the key investors in this domain?
§ Whoare the key opinion leaders / experts in this field?
§ Whatkind of partnership models are commonly adopted by industry stakeholders?
§ Whatare the factors that are likely to influence the evolution of this upcoming market?
§ How is the currentand future market opportunity likely to be distributed across key market segments?
Youmay also be interested in the following titles:
1. DNA-EncodedLibraries: Platforms and Services Market
2. GlobalStem Cells Market: Focus on Clinical Therapies, 2020–2030
Contact Details:
GauravChaudhary
+1(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
